Alzamend Neuro (ALZN) Institutional Ownership → Exposed: 10 CENT Crypto to Explode May 20th? (From True Market Insiders) (Ad) Free ALZN Stock Alerts $0.68 +0.05 (+7.34%) (As of 10:13 AM ET) Add Compare Share Share OwnershipStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for Alzamend Neuro (NASDAQ:ALZN)CurrentInstitutional OwnershipPercentage49.61%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$26.48KNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$1.92M Get ALZN Insider Trade Alerts Want to know when executives and insiders are buying or selling Alzamend Neuro stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ALZN Institutional Buying and Selling by Quarter Ad Crypto 101 Media[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. Alzamend Neuro Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/20/2024Virtu Financial LLC26,482$26K0.0%N/A0.385% 2/2/2024 Truist Financial Corp154,327$137K0.0%-93.3%2.168% 5/11/2022 RFG Advisory LLC250,000$308K0.0%N/A0.277% 5/9/2022 Qube Research & Technologies Ltd78,465$97K0.0%N/A0.087% 4/22/2022 Truist Financial Corp2,314,907$2.85M0.0%N/A2.569% 1/31/2022Commonwealth Equity Services LLC116,666$221K0.0%N/A0.131% 11/16/2021 Schonfeld Strategic Advisors LLC31,600$97K0.0%N/A0.036% 11/16/2021 Two Sigma Investments LP172,913$533K0.0%N/A0.199% 11/16/2021 Warberg Asset Management LLC14,000$43K0.0%N/A0.016% 11/15/2021 Sassicaia Capital Advisers LLC93,762$289K0.8%N/A0.108% 9/17/2021Virtu Financial LLC15,402$135K0.0%N/A0.018% 8/16/2021 Cubist Systematic Strategies LLC23,672$207K0.0%N/A0.028% 8/13/2021 Geode Capital Management LLC44,600$389K0.0%N/A0.052% 8/11/2021Susquehanna International Group LLP57,030$498K0.0%N/A0.067% (Data available from 1/1/2016 forward) ALZN Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ALZN shares? During the previous two years, the following institutional investors and hedge funds held shares of Alzamend Neuro shares: Truist Financial Corp ($137K), Virtu Financial LLC ($26K).Learn more on ALZN's institutional investors. What percentage of Alzamend Neuro stock is owned by institutional investors? 49.61% of Alzamend Neuro stock is owned by institutional investors. Learn more on ALZN's institutional investor holdings. Which institutional investors have been buying Alzamend Neuro stock? The following institutional investors have purchased Alzamend Neuro stock in the last 24 months: Virtu Financial LLC ($26.48K). How much institutional buying is happening at Alzamend Neuro? Institutional investors have bought a total of 26,482 shares in the last 24 months. This purchase volume represents approximately $26.48K in transactions. Which Alzamend Neuro major shareholders have been selling company stock? The following institutional investors have sold Alzamend Neuro stock in the last 24 months: Truist Financial Corp ($2.16M). How much institutional selling is happening at Alzamend Neuro? Institutional investors have sold a total of 2,160,580 shares in the last 24 months. This volume of shares sold represents approximately $1.92M in transactions. Related Companies: Cyclacel Pharmaceuticals Institutional Ownership Petros Pharmaceuticals Institutional Ownership Exicure Institutional Ownership Ensysce Biosciences Institutional Ownership Soligenix Institutional Ownership Clever Leaves Institutional Ownership GT Biopharma Institutional Ownership Seelos Therapeutics Institutional Ownership ZyVersa Therapeutics Institutional Ownership GeoVax Labs Institutional Ownership This page (NASDAQ:ALZN) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap Profits4 Cryptos BETTER than BitcoinTrue Market Insiders[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaBill Clinton Backing Biden Replacement???The Freeport SocietyTop 5 Tech Stocks to Buy for 2024Daily Market AlertsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarWarren Buffett's "mystery stock"Stansberry ResearchThis Could be Your “Big Money” AI MomentInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.